LivaNova (LIVN) Projected to Post Quarterly Earnings on Wednesday

LivaNova (NASDAQ:LIVN) is expected to be posting its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of $0.91 per share and revenue of $342.3180 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:00 AM ET.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $0.84 by $0.21. The business had revenue of $352.50 million during the quarter, compared to analyst estimates of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The business’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.93 earnings per share. On average, analysts expect LivaNova to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

LivaNova Trading Down 0.8%

LivaNova stock opened at $53.86 on Wednesday. The firm has a market cap of $2.94 billion, a price-to-earnings ratio of -13.85 and a beta of 0.95. LivaNova has a 1 year low of $32.48 and a 1 year high of $58.91. The firm’s 50 day moving average price is $54.56 and its two-hundred day moving average price is $47.39. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of LIVN. AQR Capital Management LLC raised its stake in shares of LivaNova by 30.5% during the 2nd quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock worth $92,201,000 after purchasing an additional 478,525 shares in the last quarter. Invesco Ltd. grew its holdings in LivaNova by 714.7% in the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock valued at $46,313,000 after buying an additional 902,447 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of LivaNova by 4.6% in the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after acquiring an additional 36,094 shares during the period. Scopia Capital Management LP acquired a new stake in shares of LivaNova in the second quarter worth $36,657,000. Finally, The Manufacturers Life Insurance Company increased its position in LivaNova by 8.7% during the second quarter. The Manufacturers Life Insurance Company now owns 512,429 shares of the company’s stock worth $23,070,000 after acquiring an additional 40,905 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on LIVN shares. Weiss Ratings restated a “sell (d-)” rating on shares of LivaNova in a report on Wednesday, October 8th. The Goldman Sachs Group set a $55.00 price target on LivaNova and gave the company a “neutral” rating in a research report on Wednesday, October 1st. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research note on Wednesday, September 3rd. Finally, Barclays lifted their target price on shares of LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 21st. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, LivaNova currently has a consensus rating of “Moderate Buy” and an average target price of $59.71.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.